ANDA Sponsors’ Tablets Should Be Close to RLD in Size, Shape

Washington Drug Letter
A A
Generics makers should design tablets and capsules to be similar in size and shape to their reference listed drug (RLD) when they seek ANDA approval, the FDA says.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00